[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 34 of about 34
1. Uematsu T, Hasegawa T, Hiraoka BY, Komatsu F, Matsuura T, Yamada AS, Yamaoka M: Multidrug resistance gene 1 expression in salivary gland adenocarcinomas and oral squamous-cell carcinomas. Int J Cancer; 2001 Apr 15;92(2):187-94
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidrug resistance gene 1 expression in salivary gland adenocarcinomas and oral squamous-cell carcinomas.
  • In combined chemotherapy for head-and-neck cancer (HNC), salivary gland-cell adenocarcinoma (SGA) shows insufficient clinical outcome, and it has been suggested that the sensitivity and/or the mechanism of resistance to anti-cancer drugs are different between SGA and oral squamous-cell carcinoma (SCC).
  • The aim of our study was to clarify whether P-glycoprotein (P-gp) expression is associated with multidrug resistance (MDR) in HNC and the difference in the process of its development between SGA and SCC.
  • In immunohistochemical analysis, P-gp expression was found in the ductal cells of salivary glands but not in oral mucosal epithelium.
  • In cancer tissues, a few SCC cells in 12 of 37 and most cells in all SGAs expressed P-gp.
  • The intensive P-gp expression was significantly found in SGA compared with SCC.
  • However, P-gp expression was developed in both HSY and Hepd cell lines after vincristine (VCR) treatment.
  • RT-PCR showed that the mean ratios of mdr1 mRNA expression levels in HSY clones were 3.7-fold higher than those in Hepd clones after VCR treatment, while each cell line exhibited both induction and activated production of P-gp.
  • These results suggest that P-gp-related MDR in SGA is an inherent phenotype caused by both high levels of P-gp induction and activated P-gp production during VCR treatment, while that in SCC is an acquired phenotype chiefly caused by induction of P-gp.
  • [MeSH-major] Adenocarcinoma / genetics. Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma, Squamous Cell / genetics. Drug Resistance, Neoplasm. Genes, MDR. Mouth Neoplasms / genetics. Salivary Gland Neoplasms / genetics. Vincristine / therapeutic use
  • [MeSH-minor] Adult. Aged. Animals. Cell Division / drug effects. Cell Survival / drug effects. Drug Resistance, Multiple. Female. Gene Expression Regulation, Neoplastic. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / genetics. Head and Neck Neoplasms / metabolism. Humans. Male. Mice. Mice, Nude. Middle Aged. P-Glycoprotein / biosynthesis. RNA, Messenger / biosynthesis. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11291044.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / P-Glycoprotein; 0 / RNA, Messenger; 5J49Q6B70F / Vincristine
  •  go-up   go-down


2. Yamamoto T, Staples J, Wataha J, Lewis J, Lockwood P, Schoenlein P, Rao S, Osaki T, Dickinson D, Kamatani T, Schuster G, Hsu S: Protective effects of EGCG on salivary gland cells treated with gamma-radiation or cis-platinum(II)diammine dichloride. Anticancer Res; 2004 Sep-Oct;24(5A):3065-73
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protective effects of EGCG on salivary gland cells treated with gamma-radiation or cis-platinum(II)diammine dichloride.
  • Dysfunction of salivary glands is often associated with aging and cancer therapy.
  • The current study investigated whether -(-) epigallocatechin-3-gallate (EGCG), the major green tea polyphenol, protects normal salivary gland cells from the effects of gamma-irradiation and the chemotherapy drug cis-platinum(II)diammine dichloride (CDDP).
  • Human immortalized salivary acinar and ductal cells, and oral squamous cell carcinoma cells were irradiated with gamma-rays or treated with CDDP, with or without pretreatment with EGCG, followed by MTT and BrdU incorporation assays.
  • The results demonstrated that EGCG protected the normal salivary gland cells from chemical or irradiation-induced damage.
  • However, protection of oral cancer cells by EGCG was also observed if EGCG was at physiologically achievable salivary concentrations but not at higher concentrations, suggesting that the combination of green tea consumption with cancer therapy requires further evaluation.
  • [MeSH-major] Catechin / analogs & derivatives. Catechin / pharmacology. Radiation Injuries / prevention & control. Radiation-Protective Agents / pharmacology. Salivary Glands / drug effects. Salivary Glands / radiation effects
  • [MeSH-minor] Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / radiotherapy. Cell Line, Tumor. Cell Survival / drug effects. Cell Survival / radiation effects. Cisplatin / adverse effects. Cisplatin / pharmacology. Cyclin D. Cyclin-Dependent Kinase 4. Cyclin-Dependent Kinase Inhibitor p21. Cyclin-Dependent Kinases / metabolism. Cyclins / metabolism. DNA / biosynthesis. Dose-Response Relationship, Drug. Dose-Response Relationship, Radiation. Gamma Rays. Humans. Mouth Neoplasms / metabolism. Mouth Neoplasms / radiotherapy. Proto-Oncogene Proteins / metabolism. Tetrazolium Salts. Thiazoles

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15517917.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA097258-01A1
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cyclin D; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Cyclins; 0 / Proto-Oncogene Proteins; 0 / Radiation-Protective Agents; 0 / Tetrazolium Salts; 0 / Thiazoles; 298-93-1 / thiazolyl blue; 8R1V1STN48 / Catechin; 9007-49-2 / DNA; BQM438CTEL / epigallocatechin gallate; EC 2.7.11.22 / CDK4 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 4; EC 2.7.11.22 / Cyclin-Dependent Kinases; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


3. Le Tourneau C: [Molecularly targeted therapy in head and neck cancer]. Bull Cancer; 2010 Dec;97(12):1453-66
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Molecularly targeted therapy in head and neck cancer].
  • The emergence of molecularly targeted therapy did not spare head and neck cancers.
  • Head and neck squamous cell carcinomas (HNSCC) were indeed one of the first tumor types to get a molecularly targeted agent approved (cetuximab, a monoclonal antibody targeting EGFR), not only in the recurrent or metastatic setting but also in the locally advanced setting.
  • This article summarizes recent data on molecularly targeted agents in most frequent head and neck cancers including HNSCC, nasopharyngeal carcinoma and adenoid cystic carcinoma of salivary glands.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Head and Neck Neoplasms / drug therapy. Molecular Targeted Therapy / methods
  • [MeSH-minor] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal, Humanized. Carcinoma, Adenoid Cystic / drug therapy. Cetuximab. Cisplatin / therapeutic use. Combined Modality Therapy / methods. Humans. Nasopharyngeal Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Protein Kinase Inhibitors / therapeutic use. Randomized Controlled Trials as Topic. Salivary Gland Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21134823.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; PQX0D8J21J / Cetuximab; Q20Q21Q62J / Cisplatin; Nasopharyngeal carcinoma
  •  go-up   go-down


Advertisement
4. Möller P, Perrier M, Ozsahin M, Monnier P: A prospective study of salivary gland function in patients undergoing radiotherapy for squamous cell carcinoma of the oropharynx. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2004 Feb;97(2):173-89
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective study of salivary gland function in patients undergoing radiotherapy for squamous cell carcinoma of the oropharynx.
  • OBJECTIVE: We sought to investigate the impact of head and neck cancer treatment on salivary function.
  • STUDY DESIGN: The study was conducted on 54 patients with advanced squamous cell carcinoma with confirmed (n = 50) or suspected (n = 4) primary oropharyngeal localization who were treated with radiation alone or in combination with surgery or chemotherapy, or both.
  • The following groups were considered in the evaluation: 1, the entire pool of patients; 2, those undergoing surgery and those not undergoing surgery before radiation; 3, those undergoing resection and those not undergoing resection of the submandibular gland.
  • RESULTS: Head and neck surgery, particularly when submandibular gland resection was performed, had a negative impact on salivary flow rates but did not influence pH or buffering capacity.
  • Nonetheless, the effect of surgery on salivary flow rates decreased progressively and disappeared at 3 to 6 months after radiotherapy.
  • More than two thirds of the salivary output was lost during radiation treatment.
  • All patients were experiencing salivary dysfunction at 1 year after completion of radiotherapy, with average decreases of 93% (P < .0001) and 95% (P < .0001) for whole resting salivary flow and whole stimulated salivary flow, respectively, compared with the preradiotherapy values.
  • CONCLUSIONS: The result of this study confirms that cancer treatment involving full-dose radiotherapy (RTH) to all major salivary glands for locally advanced squamous cell carcinoma of the oropharynx induces severe hyposalivation with alteration of salivary pH and buffering capacity.
  • Head and neck surgery has a negative impact on salivary flow rates, especially when the submandibular gland is removed.
  • However, surgery before irradiation is not a factor aggravating hyposalivation when postoperative radiotherapy includes all the major salivary glands.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Oropharyngeal Neoplasms / radiotherapy. Salivary Glands / radiation effects
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Buffers. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Hydrogen-Ion Concentration. Male. Middle Aged. Prospective Studies. Saliva / radiation effects. Secretory Rate / radiation effects. Submandibular Gland / surgery. Xerostomia / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14970776.001).
  • [ISSN] 1079-2104
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Buffers
  •  go-up   go-down


5. Zhang Q, Qing J, Wei MW, Guo ZM: [Clinical analysis of sixteen cases of lymphoepithelial carcinoma of salivary gland]. Ai Zheng; 2005 Nov;24(11):1384-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of sixteen cases of lymphoepithelial carcinoma of salivary gland].
  • BACKGROUND & OBJECTIVE: Lymphoepithelial carcinoma of salivary gland is a rare and special kind of malignant tumor, and has seldom been reported.
  • This study was to summarize the clinical features, treatment and curative effect of this disease according to our experiences.
  • METHODS: Clinical data of 16 patients with pathologically confirmed primary lymphoepithelial carcinoma of salivary gland, treated in Cancer Center of Sun Yat-sen University from Jan.
  • RESULTS: The 16 patients with lymphoepithelial carcinoma of salivary gland accounted for 3.6% of all the patients diagnosed as malignant tumors of salivary gland simultaneously in our center.
  • All patients had tumors occurred in unilateral gland, aged 15-57 years, with the female to male ratio of 1:1.
  • All patients were treated with surgery, of which 9 received surgery only, 5 received surgery plus postoperative radiotherapy, 1 received surgery plus postoperative chemoradiotherapy, 1 received surgery plus chemotherapy.
  • CONCLUSIONS: Although lymphoepithelial carcinoma of salivary gland is poorly differentiated, the prognosis of this disease is good.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Epstein-Barr Virus Infections. Lymph Nodes / pathology. Parotid Gland / surgery. Salivary Gland Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neck Dissection. Parotid Neoplasms / radiotherapy. Parotid Neoplasms / surgery. Parotid Neoplasms / therapy. Parotid Neoplasms / virology. Radiotherapy, Adjuvant. Retrospective Studies. Submandibular Gland / surgery. Submandibular Gland Neoplasms / radiotherapy. Submandibular Gland Neoplasms / surgery. Submandibular Gland Neoplasms / therapy. Submandibular Gland Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16552968.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


6. Laszlo A, Rosset A, Hermann F, Ozsahin M, Zouhair A, Mirimanoff RO: [T.i.d. accelerated radiotherapy alone or alternating with chemotherapy in patients with a locally advanced ORL cancer: analysis of late toxicity]. Cancer Radiother; 2001 Apr;5(2):130-7
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [T.i.d. accelerated radiotherapy alone or alternating with chemotherapy in patients with a locally advanced ORL cancer: analysis of late toxicity].
  • [Transliterated title] Radiothérapie trifractionnée accélérée seule ou alternée avec la chimiothérapie chez des patients souffrant d'un cancer localement évolué de la sphère ORL: analyse de la toxicité tardive.
  • PURPOSE: To assess late effects and quality of life in patients treated by three times daily (t.i.d.) radiotherapy with or without alternating chemotherapy for locally advanced squamous cell carcinoma of the head and neck.
  • PATIENTS AND METHOD: Between 1986 and 1991, 153 patients with locally advanced tumors have been included in a phase I/II study consisting of t.i.d. radiotherapy (4 h. between fractions) of 2 Gy/fraction to a total dose of 60 Gy, alternated or not with combination chemotherapy.
  • Ninety-two patients were eligible for late effect assessment: 61 in the combined modality group and 31 in the radiation therapy only group.
  • Twenty-nine patients, who were alive at the time of our study, received a questionnaire on their quality of life, and were invited for a clinical evaluation using the SOMA-LENT scale.
  • RESULTS: Ninety percent of the patients treated by radiation therapy alone developed one or more late complications.
  • Overall, 47% of the patients have developed severe complications (grade III and IV): 42% in the group treated by radiation therapy alone and 49% in the group treated with combined modality.
  • In the group treated by radiation therapy alone, the most commonly damaged organs were the mucosa (83%), skin (51%) and salivary glands (42%).
  • In the combined modality group, 95% of patients developed one or more late sequelae, of which 79% had skin, 51% mucosa and 42% salivary gland late effects, respectively.
  • Assessment according to the SOMA-LENT scale showed serious late effects mainly at the level of the salivary glands, mandibles and teeth.
  • CONCLUSION: This unconventional 4-h three times daily radiotherapy protocol resulted in very severe late effects on normal tissue.
  • However, combination with chemotherapy resulted in minimal additional toxicity.
  • [MeSH-major] Chemotherapy, Adjuvant. Dose Fractionation. Otorhinolaryngologic Neoplasms / radiotherapy. Radiation Injuries / etiology. Radiotherapy / adverse effects
  • [MeSH-minor] Combined Modality Therapy. Deglutition Disorders / epidemiology. Deglutition Disorders / etiology. Follow-Up Studies. Humans. Jaw / radiation effects. Laryngeal Diseases / epidemiology. Laryngeal Diseases / etiology. Osteoradionecrosis / epidemiology. Osteoradionecrosis / etiology. Quality of Life. Radiodermatitis / epidemiology. Radiodermatitis / etiology. Retrospective Studies. Salivary Gland Diseases / epidemiology. Salivary Gland Diseases / etiology. Severity of Illness Index. Stomatitis / epidemiology. Stomatitis / etiology. Thyroid Diseases / epidemiology. Thyroid Diseases / etiology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11355577.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


7. Kruse AL, Grätz KW: Oral carcinoma after hematopoietic stem cell transplantation--a new classification based on a literature review over 30 years. Head Neck Oncol; 2009;1:29
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral carcinoma after hematopoietic stem cell transplantation--a new classification based on a literature review over 30 years.
  • BACKGROUND: Patients undergoing hematopoietic stem cell transplantation (HSCT) have a higher risk of developing secondary solid tumors, in particular squamous cell carcinoma, because of several risk factors, including full-body irradiation (TBI), chemotherapy, and chronic graft versus host disease (GVHD).
  • In 16 out of 30 cases, the tongue was the primary location, followed by the salivary gland (10 out of 30); 56.4% appeared in a latency time of 5 to 9 years after HSCT.
  • CONCLUSION: All physicians involved in the treatment of post-HSCT patients should be aware of the increased risk, even after 5 years from the development of oral malignancy, in particular when oral graft versus host changes are visible.
  • In order to develop evidence based management, screening and offer adequate therapy as early as possible in this patient group, multicenter studies, involving oncologists and head and neck surgeons, should be established.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Mouth Neoplasms / etiology. Neoplasms, Second Primary / etiology

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997 Aug;84(2):171-4 [9269019.001]
  • [Cites] N Engl J Med. 1997 Mar 27;336(13):897-904 [9070469.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Jul;100(1):63-9 [15953918.001]
  • [Cites] Oral Oncol. 2005 Oct;41(9):865-77 [16084755.001]
  • [Cites] Clin Med Res. 2004 Nov;2(4):243-52 [15931364.001]
  • [Cites] Semin Hematol. 2006 Jan;43(1):3-10 [16412784.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Feb;101(2):175-83 [16448918.001]
  • [Cites] Dent Clin North Am. 2008 Jan;52(1):79-109, viii-ix [18154866.001]
  • [Cites] Exp Oncol. 2007 Dec;29(4):304-8 [18199988.001]
  • [Cites] Am J Dermatopathol. 2008 Oct;30(5):466-71 [18806491.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998 Dec;86(6):692-6 [9868727.001]
  • [Cites] Ann Intern Med. 1999 Nov 16;131(10):738-44 [10577296.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):348-57 [10637249.001]
  • [Cites] Br J Oral Maxillofac Surg. 2000 Aug;38(4):370-7 [10922170.001]
  • [Cites] J Oral Pathol Med. 2001 Mar;30(3):148-53 [11271629.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):464-71 [11208840.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 Jan;93(1):75-80 [11805779.001]
  • [Cites] J Oral Pathol Med. 2002 Mar;31(3):134-41 [11903818.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1352-8 [12663726.001]
  • [Cites] Am J Hematol. 2004 Oct;77(2):200-2 [15389910.001]
  • [Cites] Harvey Lect. 1966-1967;62:21-78 [4875305.001]
  • [Cites] Am J Med. 1980 Aug;69(2):204-17 [6996481.001]
  • [Cites] Exp Hematol. 1984 Sep;12(8):660-6 [6386505.001]
  • [Cites] N Engl J Med. 1989 Sep 21;321(12):784-9 [2671734.001]
  • [Cites] Cancer. 1990 Feb 1;65(3):473-6 [2297638.001]
  • [Cites] Laryngoscope. 1990 Feb;100(2 Pt 1):190-4 [2153884.001]
  • [Cites] Blood. 1991 Nov 1;78(9):2451-5 [1932758.001]
  • [Cites] Blood. 1992 Jan 1;79(1):289-91 [1728317.001]
  • [Cites] Leuk Lymphoma. 1992 Aug;7(5-6):419-23 [1493443.001]
  • [Cites] Hematol Oncol Clin North Am. 1993 Apr;7(2):417-29 [8468274.001]
  • [Cites] N Engl J Med. 1993 Oct 14;329(16):1152-7 [8377778.001]
  • [Cites] Fukushima J Med Sci. 1993 Dec;39(2):77-87 [7927138.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2187-92 [7931488.001]
  • [Cites] Bone Marrow Transplant. 1994 Jul;14(1):99-104 [7951127.001]
  • [Cites] Blood. 1996 May 1;87(9):3633-9 [8611687.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996 Nov;82(5):556-63 [8936521.001]
  • [Cites] J Oral Pathol Med. 2005 Jul;34(6):368-73 [15946186.001]
  • (PMID = 19624855.001).
  • [ISSN] 1758-3284
  • [Journal-full-title] Head & neck oncology
  • [ISO-abbreviation] Head Neck Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2724375
  • [General-notes] NLM/ Original DateCompleted: 20100629
  •  go-up   go-down


8. Ng W, Jacob S, Delaney G, Barton M: Estimation of an optimal chemotherapy utilisation rate for head and neck carcinoma: setting an evidence-based benchmark for the best-quality cancer care. Eur J Cancer; 2009 Aug;45(12):2150-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estimation of an optimal chemotherapy utilisation rate for head and neck carcinoma: setting an evidence-based benchmark for the best-quality cancer care.
  • BACKGROUND: We estimated the optimal chemotherapy utilisation rate for head and neck cancer as a benchmark for measuring and improving the quality of cancer care.
  • METHODS: An optimal chemotherapy utilisation tree was constructed using indications for chemotherapy that were identified from evidence-based treatment guidelines.
  • Data on the proportion of patient and tumour-related attributes for which chemotherapy was indicated were obtained and merged with the treatment indications to calculate the optimal utilisation rate.
  • The optimal chemotherapy utilisation rate was compared with actual utilisation rates reported.
  • RESULTS: Chemotherapy is indicated at least once in 36% (95% CI, 33-38%) of all patients with head and neck carcinoma.
  • The optimal utilisation rates by subsites were as follows: lip, 8%; oral cavity, 40%; nasopharynx, 69%; oropharynx, 66%; hypopharynx, 74%; larynx, 43%; salivary gland, 48% and paranasal sinus with nasal cavity, 38%.
  • CONCLUSIONS: The optimal proportion of patients who should receive chemotherapy in the head and neck carcinoma population has risen significantly over the past 20 years.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19285857.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


9. Jaguar GC, Lima EN, Kowalski LP, Pellizon AC, Carvalho AL, Alves FA: Impact of submandibular gland excision on salivary gland function in head and neck cancer patients. Oral Oncol; 2010 May;46(5):349-54
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of submandibular gland excision on salivary gland function in head and neck cancer patients.
  • Head and neck cancer surgery is often associated with neck dissection and usually includes the submandibular glands.
  • Literature data related to remaining salivary gland function after surgery is scarce and controversial.
  • A reduction in salivary output and increase in complaints of xerostomia have been suggested.
  • However, a compensatory salivary mechanism has also been reported.
  • The aim of this prospective study was to evaluate the effect of neck dissection (with submandibular excision) on salivary gland function measured by salivary flow rate and salivary gland scintigraphy.
  • The surgery group was composed of 37 patients, who underwent submandibular gland resection, and the non-surgery group of 43 patients evaluated prior to radiation and/or chemotherapy treatment.
  • Whole unstimulated and stimulated saliva collection and salivary gland scintigraphy were performed in all patients.
  • The mean unstimulated salivary flow was 0.60 and 0.94 m/min for the surgery and non-surgery groups, respectively (p=0.008).
  • Nevertheless, no statistical difference in the stimulated salivary flow was observed between the groups (p=0.26).
  • The data of the present study support the contention that submandibular gland resection causes a decrease in unstimulated salivary volume.
  • Consequently, the compensatory salivary mechanism seems not to be a possibility.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Head and Neck Neoplasms / surgery. Neck Dissection / adverse effects. Salivary Glands / surgery. Submandibular Gland / surgery. Xerostomia / etiology

  • Genetic Alliance. consumer health - Salivary Gland Cancer.
  • MedlinePlus Health Information. consumer health - Dry Mouth.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20227906.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


10. Hamakawa H, Nakashiro K, Sumida T, Shintani S, Myers JN, Takes RP, Rinaldo A, Ferlito A: Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer. Head Neck; 2008 Jun;30(6):800-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer.
  • BACKGROUND: Recently, attention has been focused on molecular targeted cancer therapy in various tumors.
  • Although there is no single consistent molecular target specific for oral squamous cell carcinoma (OSCC) and salivary gland cancer (SGC), there are a number of promising candidate proteins.
  • RESULTS: Gefitinib ("Iressa," ZD1839), a small molecule EGFR tyrosine kinase inhibitor, can inhibit the proliferation of OSCC cell lines in a dose- and time-dependent manner and lead to cell cycle arrest with accumulation of cells in the G1 phase, and a decrease of cells in S phase.
  • Furthermore, a cooperative antiproliferative effect was obtained when cancer cells were treated with radiation followed by gefitinib.
  • Treatment with celecoxib, a COX-2 selective inhibitor, enhanced the radioresponsiveness of HSC-2 cells, which constitutively expressed COX-2.
  • Recent studies have demonstrated that PPARgamma ligands induce cellular differentiation and inhibit cell growth in carcinomas of various types.
  • These data suggest that synthetic PPARgamma ligands may be useful for molecular targeting of oral cancer.
  • Finally, the possibility of using molecular targeted therapy directed at hormone receptors in the treatment of advanced SGCs was described.
  • Studies of different targeted agents alone or with more conventional treatment modalities are needed to fully determine what role the targeted therapy will play in the management of patients with OSCC and SGC.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy. Salivary Gland Neoplasms / drug therapy
  • [MeSH-minor] Cyclooxygenase 2 Inhibitors / therapeutic use. Humans. PPAR gamma / antagonists & inhibitors. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptors, Progesterone / antagonists & inhibitors


11. Stennert E, Kisner D, Jungehuelsing M, Guntinas-Lichius O, Schröder U, Eckel HE, Klussmann JP: High incidence of lymph node metastasis in major salivary gland cancer. Arch Otolaryngol Head Neck Surg; 2003 Jul;129(7):720-3
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High incidence of lymph node metastasis in major salivary gland cancer.
  • OBJECTIVE: To analyze the incidence and risk factors for clinically apparent and occult lymph node metastases in patients with major salivary gland cancers.
  • Patients were treated with surgery alone (55%); surgery and radiation therapy (43%); or a combination of surgery, radiation, and chemotherapy (2%).
  • Histologic diagnosis was significantly related to the incidence of lymph node metastasis: 89% (16/18) for undifferentiated carcinomas.
  • CONCLUSIONS: We found a high incidence of lymph node metastasis from major salivary gland cancers.
  • Neck dissections should be considered as an integral part of the surgical approach in patients with major salivary gland cancer, especially if no postoperative radiation therapy is planned.
  • [MeSH-major] Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / pathology. Child. Disease-Free Survival. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12874071.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


12. Naramoto H, Uematsu T, Uchihashi T, Doto R, Matsuura T, Usui Y, Uematsu S, Li X, Takahashi M, Yamaoka M, Furusawa K: Multidrug resistance-associated protein 7 expression is involved in cross-resistance to docetaxel in salivary gland adenocarcinoma cell lines. Int J Oncol; 2007 Feb;30(2):393-401
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidrug resistance-associated protein 7 expression is involved in cross-resistance to docetaxel in salivary gland adenocarcinoma cell lines.
  • For in vitro and in vivo chemotherapeutic studies, we used the following head and neck cancer cell lines: a mouse oral squamous cell carcinoma (SCC) cell line, Sq-1979; a human SCC cell line, SCCHA; a mouse salivary gland adenocarcinoma (SGA) cell line, NR-PG; and a human SGA cell line, HSY.
  • We used a vinca alkaloid anticancer drug, vincristine (VCR), as a chemotherapeutic anticancer drug.
  • To determine the cause of multidrug resistance, Western blot analysis, reverse transcription-polymerase chain reaction (RT-PCR), immunohistochemistry of xenografted tumors in nude mice, drug efflux analysis, and drug efflux inhibitory assays were performed.
  • VCR-treated cell lines, Sq-1979/VCR, SCCHA/VCR, NR-PG/VCR, and HSY/VCR, intensively expressed multidrug resistance (MDR) gene 1 mRNA and multidrug resistance associated protein (MRP) 1 mRNA.
  • In each cell clone of NR-PG/VCR and HSY/VCR, MRP7 mRNA was induced by VCR treatment, suggesting an acquired resistance to VCR in the context of MRP7 expression.
  • Furthermore, doxorubicin accumulation was increased and drug cross-resistance to docetaxel decreased in HSY/VCR in the presence of a competitive MRP7 inhibitor, 17-beta-estradiol-(17-beta-D-glucuronide).
  • These results indicate that MDR1 expression, MRP1 expression, and MRP7 expression are refractory factors in head and neck cancer chemotherapy and suggest that induction of MRP7 expression is involved in drug resistance to natural products, especially to docetaxel in SGA.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / pharmacology. Drug Resistance, Multiple. Gene Expression Regulation, Neoplastic. Multidrug Resistance-Associated Proteins / biosynthesis. Salivary Gland Neoplasms / drug therapy. Taxoids / pharmacology
  • [MeSH-minor] Animals. Cell Line, Tumor. Estradiol / analogs & derivatives. Estradiol / pharmacology. Female. Head and Neck Neoplasms. Humans. Immunohistochemistry. Mice. Mice, Nude. Neoplasm Transplantation. RNA, Messenger / metabolism

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17203221.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / ABCC10 protein, human; 0 / Antineoplastic Agents; 0 / Multidrug Resistance-Associated Proteins; 0 / RNA, Messenger; 0 / Taxoids; 15H5577CQD / docetaxel; 1806-98-0 / estradiol-17 beta-glucuronide; 4TI98Z838E / Estradiol
  •  go-up   go-down


13. Diaz EM Jr, Kies MS: Chemotherapy for skull base cancers. Otolaryngol Clin North Am; 2001 Dec;34(6):1079-85, viii

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy for skull base cancers.
  • This article focuses on treatment options for select skull base problems that have decreased post-treatment morbidity and, in many cases, improved survival.
  • The select skull base cancers covered include nasopharyngeal carcinoma, squamous cell carcinoma of the paranasal sinuses, sinonasal undifferentiated carcinoma, neuroendocrine carcinoma, esthesioneuroblastoma, and salivary gland carcinoma.
  • [MeSH-major] Skull Base Neoplasms / drug therapy
  • [MeSH-minor] Carcinoma, Adenoid Cystic / drug therapy. Carcinoma, Neuroendocrine / drug therapy. Carcinoma, Squamous Cell / drug therapy. Esthesioneuroblastoma, Olfactory / drug therapy. Humans. Paranasal Sinus Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11728933.001).
  • [ISSN] 0030-6665
  • [Journal-full-title] Otolaryngologic clinics of North America
  • [ISO-abbreviation] Otolaryngol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 29
  •  go-up   go-down


14. Rosenthal DI, Chambers MS, Weber RS, Eisbruch A: A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing. Semin Oncol; 2004 Dec;31(6 Suppl 18):25-8
Hazardous Substances Data Bank. AMIFOSTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
  • Intensity modulated radiation therapy (IMRT) allows for relative parotid salivary gland sparing for patients undergoing treatment for head and neck squamous cell cancer, but is less reliable for sparing the submandibular glands.
  • Cytoprotection with amifostine (Ethyol; Medimmune Inc, Gaithersburg, MD) has been shown to decrease rates of acute and late xerostomia in patients undergoing radiation therapy for head and neck squamous cell cancer.
  • The addition of amifostine to IMRT may augment parotid salivary sparing, and add submandibular/sublingual, and minor salivary gland sparing resulting in greater salivary flow rates and a more physiologic saliva.
  • Eligible patients include those slated to receive definitive IMRT for early oropharynx cancer or postoperative RT, both without chemotherapy, for more advanced cancers.
  • Clinical target volume (CTV) 1 will receive 60 to 66 Gy, CTV2 will receive 60 Gy, and CTV3 will receive 54 to 57 Gy.
  • The mean dose goal for the parotid gland is 25 Gy.
  • Whole mouth and individual major salivary gland stimulated and unstimulated saliva will be collected before and after therapy at 6 weeks, 6 and 12 months.
  • Xerostomia outcomes will be correlated with salivary dose volume histogram data.
  • The results of this study will give an indication of the objective and subjective benefit of combined IMRT physical parotid salivary sparing and amifostine chemical cytoprotection for combined salivary gland sparing and reduction in the rate of xerostomia in patients undergoing IMRT for head and neck squamous cell cancer.
  • [MeSH-major] Amifostine / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Parotid Gland / radiation effects. Radiation-Protective Agents / therapeutic use. Submandibular Gland / radiation effects

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15726519.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiation-Protective Agents; M487QF2F4V / Amifostine
  •  go-up   go-down


15. Jha N, Seikaly H, Harris J, Williams D, Sultanem K, Hier M, Ghosh S, Black M, Butler J, Sutherland D, Kerr P, Barnaby P: Phase III randomized study: oral pilocarpine versus submandibular salivary gland transfer protocol for the management of radiation-induced xerostomia. Head Neck; 2009 Feb;31(2):234-43
Hazardous Substances Data Bank. PILOCARPINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III randomized study: oral pilocarpine versus submandibular salivary gland transfer protocol for the management of radiation-induced xerostomia.
  • BACKGROUND: Xerostomia is a serious morbidity of radiation treatment in head and neck cancer.
  • METHODS: We conducted a prospective phase III multicenter randomized study comparing submandibular salivary gland transfer (SGT) procedure with pilocarpine during and for 3 months after XRT.
  • Salivary flow (baseline, stimulated) and University of Washington Quality of Life Questionnaire (U of W QOL) scores were measured.
  • RESULTS.: An interim intent to treat analysis (120 patients) at 6 months shows superior results in SGT arm: median baseline salivary flow for SGT (0.04 mL/minute) versus pilocarpine (0.01 mL/minute), p = .001; median stimulated salivary flow (0.18 mL/minute) for SGT versus (0.05 mL/minute) for pilocarpine, p = .003.
  • CONCLUSIONS: Submandibular SGT procedure is superior to pilocarpine in management of radiation-induced xerostomia.
  • [MeSH-major] Muscarinic Agonists / therapeutic use. Pilocarpine / therapeutic use. Submandibular Gland / transplantation. Xerostomia / drug therapy. Xerostomia / surgery
  • [MeSH-minor] Administration, Oral. Aged. Carcinoma, Squamous Cell / radiotherapy. Disease-Free Survival. Female. Head and Neck Neoplasms / radiotherapy. Humans. Male. Middle Aged. Prospective Studies. Radiotherapy / adverse effects. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Dry Mouth.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19107948.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Muscarinic Agonists; 01MI4Q9DI3 / Pilocarpine
  •  go-up   go-down


16. Nakashiro K, Begum NM, Uchida D, Kawamata H, Shintani S, Sato M, Hamakawa H: Thiazolidinediones inhibit cell growth of human oral squamous cell carcinoma in vitro independent of peroxisome proliferator-activated receptor gamma. Oral Oncol; 2003 Dec;39(8):855-61
Hazardous Substances Data Bank. PIOGLITAZONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thiazolidinediones inhibit cell growth of human oral squamous cell carcinoma in vitro independent of peroxisome proliferator-activated receptor gamma.
  • Recently, we have demonstrated that PPARgamma is expressed in human salivary gland tumors and its ligands inhibit the growth of cultured salivary gland cancer cells.
  • However, expression and function of PPARgamma in normal and neoplastic human oral squamous epithelium remains unclear.
  • In the present study, we examined PPARgamma expression in human oral squamous cell carcinoma (OSCC) and tested its ligands for any antitumor effect.
  • PPARgamma mRNA was detected by RT-PCR in some OSCC tissues and cultured cells, but the PPARgamma protein showed neither expression nor ligand-induced transcriptional activity.
  • Despite loss of PPARgamma function, synthetic PPARgamma ligands caused significant dose-dependent inhibition of cancer cell growth.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy. Thiazolidinediones / therapeutic use
  • [MeSH-minor] Cell Line, Tumor. Chromans / therapeutic use. DNA Mutational Analysis. Humans. RNA, Messenger / analysis. Receptors, Cytoplasmic and Nuclear / genetics. Receptors, Cytoplasmic and Nuclear / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Transcription Factors / genetics. Transcription Factors / metabolism. Transfection / methods

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 13679209.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chromans; 0 / RNA, Messenger; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Thiazolidinediones; 0 / Transcription Factors; I66ZZ0ZN0E / troglitazone; X4OV71U42S / pioglitazone
  •  go-up   go-down


17. Hey J, Setz J, Gerlach R, Vordermark D, Gernhardt CR, Kuhnt T: Effect of Cisplatin on parotid gland function in concomitant radiochemotherapy. Int J Radiat Oncol Biol Phys; 2009 Dec 1;75(5):1475-80
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of Cisplatin on parotid gland function in concomitant radiochemotherapy.
  • PURPOSE: To determine the influence of concomitant radiochemotherapy with cisplatin on parotid gland tissue complication probability.
  • METHODS AND MATERIALS: Patients treated with either radiotherapy (n = 61) or concomitant radiochemotherapy with cisplatin (n = 36) for head-and-neck cancer were prospectively evaluated.
  • Stimulated salivary flow rates were measured before, during the 2(nd) and 6(th) weeks and at 4 weeks and 6 months after the treatment.
  • The data were fit using the normal tissue complication probability model of Lyman.
  • Complication was defined as a reduction of the salivary flow rate to less than 25% of the pretreatment flow rate.
  • RESULTS: The normal tissue complication probability model parameter TD(50) (the dose leading to a complication probability of 50%) was found to be 32.2 Gy at 4 weeks and 32.1 Gy at 6 months for concomitant radiochemotherapy and 41.1 Gy at 4 weeks and 39.6 Gy at 6 months for radiotherapy.
  • The tolerated dose for concomitant radiochemotherapy was at least 7 to 8 Gy lower than for radiotherapy alone at TD(50).
  • CONCLUSIONS: In this study, the concomitant radiochemotherapy tended to cause a higher probability of parotid gland tissue damage.
  • [MeSH-major] Cisplatin / adverse effects. Head and Neck Neoplasms. Parotid Gland. Radiation Injuries. Radiation-Sensitizing Agents / adverse effects. Salivation / drug effects
  • [MeSH-minor] Adult. Aged. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / physiopathology. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy / adverse effects. Combined Modality Therapy / methods. Dose Fractionation. Female. Humans. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / physiopathology. Laryngeal Neoplasms / radiotherapy. Male. Middle Aged. Models, Statistical. Mouth Neoplasms / drug therapy. Mouth Neoplasms / physiopathology. Mouth Neoplasms / radiotherapy. Prospective Studies. Radiotherapy, Conformal / adverse effects. Time Factors

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19515505.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


18. Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, Leemans CR, Aaronson NK, Slotman BJ: Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol; 2008 Aug 1;26(22):3770-6
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy.
  • PURPOSE: To investigate the impact of treatment-related toxicity on health-related quality of life (HRQoL) among patients with head and neck squamous cell carcinoma treated with radiotherapy either alone or in combination with chemotherapy or surgery.
  • Toxicity was scored according to the European Organisation for Research and Treatment of Cancer (EORTC)/Radiation Therapy Oncology Group (RTOG) late radiation-induced morbidity scoring system.
  • RESULTS: Of the six RTOG scales investigated, two significantly affected self-reported HRQoL, salivary gland (RTOG(xerostomia)) and esophagus/pharynx (RTOG(swallowing)).
  • These findings suggest that the development of new radiation-induced delivery techniques should not only focus on reduction of the dose to the salivary glands, but also on anatomic structures that are involved in swallowing.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / radiotherapy. Quality of Life. Radiation Injuries / etiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Deglutition / radiation effects. Female. Health Status Indicators. Humans. Male. Middle Aged. Patient Compliance. Prospective Studies. Radiotherapy / adverse effects. Surveys and Questionnaires. Time Factors. Treatment Outcome. Xerostomia / etiology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18669465.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Tribius S, Petersen C, Knecht R, Ihloff AS: [Radiation therapy in head and neck cancer. Highlights from ASCO 2010]. HNO; 2010 Dec;58(12):1168-73

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radiation therapy in head and neck cancer. Highlights from ASCO 2010].
  • Despite new data presented at the annual congress of the American Society of Clinical Oncology (ASCO), questions remain unanswered in two basic categories: (a) How do we use IMRT with other important advances in head and neck cancer treatment, such as altered fractionation, chemotherapy, and novel agents?
  • (b) Does IMRT in its current form produce sufficient risk:benefit improvements in salivary gland sparing/less xerostomia, better targeting/local control and less late toxicity?
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Otorhinolaryngologic Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated
  • [MeSH-minor] Aged. Combined Modality Therapy. Dose Fractionation. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Quality of Life. Radiation Injuries / etiology. Radiotherapy, Conformal. Survival Rate. Thyroid Neoplasms / mortality. Thyroid Neoplasms / pathology. Thyroid Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2010 Sep 1;28(25):e445-6; author reply e447 [20606099.001]
  • (PMID = 20963390.001).
  • [ISSN] 1433-0458
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] Congresses; English Abstract
  • [Publication-country] Germany
  •  go-up   go-down


20. Zheng JW, Qiu WL, Zhang ZY: Combined and sequential treatment of oral and maxillofacial malignancies: an evolving concept and clinical protocol. Chin Med J (Engl); 2008 Oct 5;121(19):1945-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined and sequential treatment of oral and maxillofacial malignancies: an evolving concept and clinical protocol.
  • OBJECTIVE: To introduce the concept and rational regimens and present the latest development of combined treatment of oral and maxillofacial malignancies.
  • Data sources The related published literature was searched through the CNKI database and MEDLINE using the terms of oral cancer, oral and maxillofacial malignancies, combined and sequential therapy, multidisciplinary approach.
  • RESULTS: The results show that oral and maxillofacial malignancies diagnosed at an early stages (stages I and II) can be well treated with surgery alone and/or radiotherapy with optimal outcome, but advanced or recurrent diseases should be treated with rational combined and sequential treatment modalities.
  • The use of concomitant chemoradiotherapy, taxane-containing, three-drug induction regimens and Cetuximab in combination with chemotherapy or radiotherapy demonstrated favorable results in previously untreated patients with head and neck squamous cell carcinoma.
  • CONCLUSIONS: The concept of combined and sequential treatment of advanced oral and maxillofacial malignancies should be widely accepted, and the rational regimen for individual and each type of entity should be determined based on the anatomical site and the patient's performance status.
  • [MeSH-major] Facial Neoplasms / therapy. Maxillary Neoplasms / therapy. Mouth Neoplasms / therapy
  • [MeSH-minor] Carcinoma, Squamous Cell / therapy. Combined Modality Therapy. Humans. Lymphoma / therapy. Melanoma / therapy. Salivary Gland Neoplasms / therapy. Sarcoma / therapy

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Chin Med J (Engl). 2008 Oct 5;121(19):1859-60 [19080113.001]
  • (PMID = 19080129.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] China
  • [Number-of-references] 27
  •  go-up   go-down


21. Pajor A, Murlewska A, Józefowicz-Korczyńska M: [Tonsillar carcinoma--clinical assessment and analysis of treatment results]. Otolaryngol Pol; 2002;56(3):319-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tonsillar carcinoma--clinical assessment and analysis of treatment results].
  • The aim of the study was an evaluation of the clinical signs and treatment results of the patients with tonsillar cancer treated in the ENT Clinic Medical University in Łódź during 10 years (1985-1994).
  • The most frequent treatment modality was combined therapy (surgery with radio/chemotherapy) introduced in 25 persons (62.5%), surgery alone was performed in 10 cases (25%).
  • Distant metastases developed in 6 patients (15%) and the second primary neoplasm in 5 patients (12.5%).
  • We stress the importance of careful clinical assessment before planning the treatment.
  • [MeSH-major] Carcinoma, Squamous Cell. Tonsillar Neoplasms
  • [MeSH-minor] Carcinoma, Adenoid Cystic / radiotherapy. Carcinoma, Adenoid Cystic / surgery. Combined Modality Therapy. Disease-Free Survival. Humans. Radiotherapy, Adjuvant. Retrospective Studies. Salivary Gland Neoplasms / radiotherapy. Salivary Gland Neoplasms / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12162020.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


22. Hoque MO, Kawamata H, Nakashiro KI, Omotehara F, Shinagawa Y, Hino S, Begum NM, Uchida D, Yoshida H, Sato M, Fujimori T: Dihydropyrimidine dehydrogenase mRNA level correlates with the response to 5-fluorouracil-based chemo-immuno-radiation therapy in human oral squamous cell cancer. Int J Oncol; 2001 Nov;19(5):953-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dihydropyrimidine dehydrogenase mRNA level correlates with the response to 5-fluorouracil-based chemo-immuno-radiation therapy in human oral squamous cell cancer.
  • In this study, we examined the mRNA levels of DPD and TS in 28 oral squamous cell carcinomas (SCC), and 22 salivary gland tumors by semi-quantitative reverse transcription polymerase chain reaction.
  • Then we examined the correlation of the responsiveness of the patients with oral SCC to 5-FU with the intra-tumoral levels of DPD and TS mRNA.
  • All specimens were obtained at the biopsy before treatment, and then the patients were treated by oral administration of a 5-FU compound (UFT), the irradiation of cobalt-60 (upto 60 Gy) and injection of an immuno-potentiator (OK-432).
  • However, intra-tumoral levels of DPD mRNA did not correlate with the local recurrence of the tumor during the observation period after initial treatment with or without surgical resection of the residual tumors.
  • These observations suggest that intra-tumoral levels of DPD mRNA may predict the tumor response to 5-FU-based chemo-immuno-radiation therapy in the patients with oral SCC.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Cobalt Radioisotopes / therapeutic use. Fluorouracil / therapeutic use. Oxidoreductases / genetics. Picibanil / therapeutic use. RNA, Messenger / metabolism. Salivary Gland Neoplasms / therapy
  • [MeSH-minor] Antimetabolites, Antineoplastic / therapeutic use. Biopsy. Combined Modality Therapy. DNA Primers / chemistry. Dihydrouracil Dehydrogenase (NADP). Drug Resistance, Neoplasm. Humans. Immunotherapy. Reverse Transcriptase Polymerase Chain Reaction. Thymidylate Synthase / genetics. Thymidylate Synthase / metabolism. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11604993.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Cobalt Radioisotopes; 0 / DNA Primers; 0 / RNA, Messenger; 39325-01-4 / Picibanil; EC 1.- / Oxidoreductases; EC 1.3.1.2 / Dihydrouracil Dehydrogenase (NADP); EC 2.1.1.45 / Thymidylate Synthase; U3P01618RT / Fluorouracil
  •  go-up   go-down


23. Numata T, Hiruma K, Tsukuda T, Asano T: [Malignant mixed tumor]. Gan To Kagaku Ryoho; 2004 Mar;31(3):314-7
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The term "malignant mixed tumor" is usually synonymous with "carcinoma in pleomorphic adenoma," a secondary carcinoma developing in pre-existing pleomorphic adenoma.
  • However, it sometimes indicates a group of tumors consisting of carcinoma in pleomorphic adenoma, carcinosarcoma (true malignant mixed tumor) and metastasizing benign mixed tumor, the latter 2 being the most infrequent.
  • According to the data of the Japanese committee on TNM classification for salivary gland carcinomas, carcinoma in pleomorphic adenoma accounted for about 10% of all salivary gland carcinomas, both in the parotid and submandibular glands.
  • The main type of carcinomas arising in pleomorphic adenoma were undifferentiated carcinoma, adenocarcinoma and squamous cell carcinoma.
  • The treatment of choice for carcinoma in pleomorphic adenoma has consisted of en-bloc excision with wide margin.
  • Invasive growth, facial nerve involvement, lymph node metastasis or high-grade malignant tumor are grounds for postoperative radiation therapy.
  • The role of chemotherapy has not yet been well established.
  • [MeSH-major] Mixed Tumor, Malignant. Salivary Gland Neoplasms
  • [MeSH-minor] Adenoma, Pleomorphic / diagnosis. Carcinosarcoma / diagnosis. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15045931.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


24. Moreno-Jiménez M, Valero J, López-Picazo JM, Arbea L, Aristu J, Cambeiro M, Alcalde J, Martínez-Monge R: Concomitant cisplatin, paclitaxel, and hyperfractionated radiotherapy in locally advanced head and neck cancer: comparison of two different schedules. Am J Clin Oncol; 2010 Apr;33(2):137-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant cisplatin, paclitaxel, and hyperfractionated radiotherapy in locally advanced head and neck cancer: comparison of two different schedules.
  • PURPOSE: To determine feasibility and efficacy of concurrent paclitaxel and cisplatin with definitive hyperfractionated radiotherapy (HFRT) in locally advanced head-and-neck squamous cell carcinoma (HNSCC).
  • PATIENTS AND METHODS: Forty-two patients stages III to IV head-and-neck squamous cell carcinoma were enrolled in 2 consecutive prospective trials from August 1998 to January 2006.
  • In study 1, 16 patients received HFRT in 2 courses of 39.6 Gy each with a split of 2 weeks with concurrent paclitaxel (175 mg/m) and cisplatin (100 mg/m) on days 1, 21, 36, and 57.
  • In study 2, 26 patients received a continuous course of 74.4 Gy of HFRT with concurrent weekly paclitaxel (50 mg/m) and cisplatin (30 mg/m).
  • RESULTS: Tumor locations included oropharynx 48%, hypopharynx 24%, larynx 12%, paranasal sinuses 7%, salivary gland 2%, oral cavity 2% and unknown primary 5%.
  • In study 1, all patients received 3 to 4 cycles of chemotherapy and completed the programmed radiotherapy course.
  • In study 2, 69% received 5 to 6 cycles of chemotherapy and 92% completed the irradiation.
  • Efficacy and toxicity in studies.1 and 2 were not different despite completely different treatment strategies (chemotherapy dose intensity vs. radiotherapy dose intensity).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Dose Fractionation. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Prospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19786847.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


25. Langer CJ, Duffy K, Horwitz EM, Litwin S, Rosvold E, Schol J, Keenan E, Nicolaou N, Friedman CD, Ridge JA: Phase I trial of concurrent hyperfractionated split course radiotherapy (HFx RT), cisplatin (cDDP), and paclitaxel in patients with recurrent, previously irradiated, or treatment-naïve locally advanced upper aerodigestive malignancy. Cancer Invest; 2006 Mar;24(2):164-73
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of concurrent hyperfractionated split course radiotherapy (HFx RT), cisplatin (cDDP), and paclitaxel in patients with recurrent, previously irradiated, or treatment-naïve locally advanced upper aerodigestive malignancy.
  • PURPOSE: Phase I study to determine the maximally tolerated dose (MTD) of cisplatin (cDDP), paclitaxel (P), and concurrent split course hyperfractionated (BID) RT in advanced squamous cell carcinoma of the head and neck (SCCHN) and other upper aerodigestive tumors.
  • MATERIALS AND METHODS: Eligibility stipulated ECOG performance status 0-2 and either Tx-naïve, locally advanced, or locally recurrent, previously radiated, surgically unresectable upper aerodigestive cancer.
  • Previously radiated patients received 150 cGy bid x 5, wk 1; then 120 cGy bid x 5 Q 2 wk x 3 (later increased to 150 cGy BID for the entire treatment).
  • Treatment fields included recurrent tumor only with 2 cm margins.
  • Granulocyte colony stimulating factor (G-CSF) days 6-12 (off treatment week) was added if cumulative neutropenia precipitated treatment delays.
  • Eight had received prior chemotherapy, 27 prior RT.
  • At dose level three, regular treatment delays of >or=1 week due to slow neutrophil recovery occurred.
  • Addition of G-CSF (dose level 3b) reduced treatment delays from 100 percent to 28 percent and decreased the incidence of Grade >or=2 neutropenia and mucositis.
  • Six of 7 patients at this dose level completed all 4 cycles of treatment and all received full dose RT (60 Gy).
  • Median time to progression in this group was 6 months, with median and one-year survival of 9.5 mos and 41 percent, respectively.
  • CONCLUSION: Concurrent daily cisplatin/paclitaxel and split course hyperfractionated RT (60 Gy) is feasible in previously radiated patients.
  • G-CSF, administered between each cycle, reduces the incidence of treatment delays.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carcinoma, Squamous Cell / therapy. Dose Fractionation. Head and Neck Neoplasms / therapy. Lung Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Drug Administration Schedule. Ear Neoplasms / mortality. Ear Neoplasms / therapy. Female. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Male. Maximum Tolerated Dose. Middle Aged. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Radiation-Sensitizing Agents / therapeutic use. Recombinant Proteins. Salivary Gland Neoplasms / mortality. Salivary Gland Neoplasms / therapy. Survival Analysis

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16537186.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiation-Sensitizing Agents; 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


26. Bennett CL, Lane D, Stinson T, Glatzel M, Buntzel J: Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Invest; 2001;19(2):107-13
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany.
  • 28 patients with squamous cell carcinomas of the head and neck received adjunctive or primary radiotherapy (5 days per week with daily fractions of 2 Gy, up to a total dose of 60 Gy) in conjunction with carboplatin (70 mg/m2) on days 1-5 and days 21-26.
  • All patients received radiation encompassing at least 75% of the major salivary glands.
  • The patients receiving amifostine accrued significantly lower supportive care costs for resources related to infection ($241 vs. $1,275, p < 0.01), red blood cell and platelet support ($286 vs. $1,276 p = 0.06) alimentation ($343 vs. $894, p = .01), and hospitalization ($286 vs. $2,429, p < 0.01).
  • Our results from a randomized phase II trial indicate that selective cytoprotection with amifostine potentially offers clinical and economic benefits in patients with advanced head and neck cancer receiving radiochemotherapy.
  • [MeSH-major] Amifostine / economics. Amifostine / therapeutic use. Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Combined Modality Therapy. Costs and Cost Analysis. Female. Germany. Hospitalization / economics. Humans. Male. Middle Aged. Radiation-Protective Agents / adverse effects. Radiation-Protective Agents / economics. Radiation-Protective Agents / therapeutic use. Radiotherapy / adverse effects. Radiotherapy Dosage. Salivary Gland Neoplasms / drug therapy. Salivary Gland Neoplasms / radiotherapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AMIFOSTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11296615.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiation-Protective Agents; BG3F62OND5 / Carboplatin; M487QF2F4V / Amifostine
  •  go-up   go-down


27. Yoo GH, Subramanian G, Piechocki MP, Ensley JF, Kucuk O, Tulunay OE, Lonardo F, Kim H, Won J, Stevens T, Lin HS: Effect of docetaxel on the surgical tumor microenvironment of head and neck cancer in murine models. Arch Otolaryngol Head Neck Surg; 2008 Jul;134(7):735-42
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of docetaxel on the surgical tumor microenvironment of head and neck cancer in murine models.
  • OBJECTIVES: To identify the antitumor activity and wound-healing effect of docetaxel delivered in the surgical tumor microenvironment of head and neck squamous cell carcinoma (HNSCC).
  • INTERVENTION: Intrawound (IW) docetaxel therapy was tested in 3 HNSCC xenograft and 2 taxane-resistant models.
  • Intratumoral (IT) docetaxel therapy was further tested in the 2 taxane-resistant models.
  • RESULTS: In a pilot study using BALB/c mice, IW docetaxel therapy was not associated with problems in wound healing.
  • Using taxane-resistant xenograft lung cancer (H460/T800) and syngeneic salivary cancer (BALB/c mucoepidermoid carcinoma) models, IW therapy did not delay tumor growth.
  • An antitumor effect was detected with repeated docetaxel injections in the H460/T800 taxane-resistant model but not in the BALB/c mucoepidermoid carcinoma model.
  • CONCLUSIONS: These preclinical results support further testing of IW docetaxel treatment in HNSCC.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma, Squamous Cell / pathology. Disease Models, Animal. Otorhinolaryngologic Neoplasms / pathology. Taxoids / pharmacology. Wound Healing / drug effects
  • [MeSH-minor] Animals. Carcinoma, Mucoepidermoid / pathology. Carcinoma, Non-Small-Cell Lung / pathology. Cell Division / drug effects. Cell Line, Tumor. Cell Survival / drug effects. Drug Resistance, Neoplasm. Injections, Intralesional. Lung Neoplasms / pathology. Mice. Mice, Inbred BALB C. Mice, SCID. Neoplasm Transplantation. Pilot Projects. Salivary Gland Neoplasms / pathology. Tumor Burden

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18645124.001).
  • [ISSN] 1538-361X
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Taxoids; 15H5577CQD / docetaxel
  •  go-up   go-down


28. Thorstad WL, Chao KS, Haughey B: Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer. Semin Oncol; 2004 Dec;31(6 Suppl 18):8-12
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer.
  • Standard conventional radiation therapy for advanced head and neck tumors typically involves administering high radiation dose to the major salivary glands bilaterally.
  • The degree of xerostomia has been reported to depend on the radiation dose and volume of salivary gland irradiated.
  • Several studies show dose-volume-response relationships in the salivary glands, suggesting the possibility of significant improvement in saliva production postradiation, as well as quality of life, if radiation techniques can spare the salivary glands.
  • A growing body of literature supports the premise that intensity-modulated radiation therapy (IMRT) allows irradiation of tumor targets in the head and neck while sparing substantial portions of salivary glands.
  • Early clinical experience has shown substantial sparing of salivary flow following IMRT, and suggests at least equal tumor control but improved xerostomia compared with patients receiving standard radiation techniques.
  • We hypothesize that the addition of a radiation protector, such as amifostine (Ethyol; Medimmune Inc, Gaithersburg, MD) may further improve salivary function over that obtained with IMRT alone.
  • To test this hypothesis, we have initiated a pilot clinical trial to compare unstimulated and stimulated salivary flow rates 6 months and 1 year after IMRT + amifostine with historic controls treated with IMRT alone.
  • [MeSH-major] Amifostine / adverse effects. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / radiotherapy. Radiation-Protective Agents / adverse effects. Xerostomia / prevention & control
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Injections, Subcutaneous. Patient Compliance. Pilot Projects. Postoperative Period. Radiation Dosage. Radiation Injuries / etiology. Radiotherapy Dosage. Salivary Glands / drug effects. Salivation / drug effects

  • MedlinePlus Health Information. consumer health - Dry Mouth.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. AMIFOSTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15726516.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiation-Protective Agents; M487QF2F4V / Amifostine
  •  go-up   go-down


29. Shi YQ, Fukai T, Sakagami H, Kuroda J, Miyaoka R, Tamura M, Yoshida N, Nomura T: Cytotoxic and DNA damage-inducing activities of low molecular weight phenols from rhubarb. Anticancer Res; 2001 Jul-Aug;21(4A):2847-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among them, emodin and aloe-emodin showed higher cytotoxic activities against human oral squamous cell carcinoma (HSC-2) and salivary gland tumor (HSG) cell lines than against normal human gingival fibroblasts (HGF).
  • The other glycosides of anthraquinone or stilbene showed weaker cytotoxic activity against these tumor cell lines, but may be considered as cancer chemopreventive agents.
  • [MeSH-minor] Bacillus subtilis / drug effects. Carcinoma, Squamous Cell / drug therapy. Drug Screening Assays, Antitumor. Glycosides / isolation & purification. Glycosides / toxicity. Humans. Microbial Sensitivity Tests. Molecular Weight. Mouth Neoplasms / drug therapy. Plant Extracts / chemistry. Plant Extracts / isolation & purification. Plant Roots / chemistry. Tumor Cells, Cultured

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11724365.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Glycosides; 0 / Phenols; 0 / Plant Extracts
  •  go-up   go-down


30. Razak AR, Siu LL, Le Tourneau C: Molecular targeted therapies in all histologies of head and neck cancers: an update. Curr Opin Oncol; 2010 May;22(3):212-20
Hazardous Substances Data Bank. CETUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular targeted therapies in all histologies of head and neck cancers: an update.
  • PURPOSE OF REVIEW: This article reviewed the recent developments in molecular targeted therapy in head and neck cancers.
  • RECENT FINDINGS: The use of cetuximab in squamous cell head and neck cancer is associated with clinical benefit and, in some cases, survival.
  • Combination therapy of molecular targeted agents with chemoradiation in the locally advanced setting of head and neck squamous cell carcinomas and nasopharyngeal cancer shows early promising results, but at the expense of increased toxicity.
  • In malignant salivary gland tumors, the evaluation of targeted therapy has been disappointing.
  • New therapeutic targets warrant further evaluation in these cancers.
  • SUMMARY: Despite the encouraging results achieved with antiepidermal growth factor receptor therapy, particularly with cetuximab, targeted therapy trials conducted in head and neck cancers to date have largely lacked efficacy or are associated with significant toxicity.
  • The recent identification of improved prognosis among head and neck squamous cell carcinoma patients whose tumors harbor the human papilloma virus may allow better treatment selection for these patients, while the identification of a hallmark gene fusion transcript in adenocystic carcinoma may herald new treatment promise.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / therapy. Drug Delivery Systems / methods. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Cetuximab. Clinical Trials as Topic. Combined Modality Therapy. Humans. Radiotherapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20173639.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; PQX0D8J21J / Cetuximab
  • [Number-of-references] 77
  •  go-up   go-down


31. Tijink BM, De Bree R, Van Dongen GA, Leemans CR: How we do it: Chemo-electroporation in the head and neck for otherwise untreatable patients. Clin Otolaryngol; 2006 Oct;31(5):447-51
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Keypoints * Chemo-electroporation therapy with bleomycin is a locoregional treatment modality for head and neck and skin cancer, with the potential to preserve function.
  • * In our institution, chemo-electroporation therapy is used for patients that can no longer be treated by surgery or radiotherapy, or for whom surgical treatment would be very extensive and thus declined by the patient.
  • * This paper describes in detail the technique of bleomycin-electroporation therapy.
  • * The main focus of the trial is to determine the safety, effectiveness, and burden of bleomycin-electroporation therapy for the patient.
  • * All 17 tumours responded to therapy.
  • * Based on the outcome of the clinical trial, bleomycin-electroporation therapy has the potential to become a valuable addition to the late-stage treatment options for patients with head and neck or skin tumours.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Bleomycin / therapeutic use. Electroporation / methods. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / secondary. Adenocarcinoma / therapy. Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / secondary. Carcinoma, Basal Cell / therapy. Carcinoma, Merkel Cell / secondary. Carcinoma, Merkel Cell / therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Melanoma / secondary. Melanoma / therapy. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Netherlands. Salivary Gland Neoplasms / secondary. Salivary Gland Neoplasms / therapy. Sarcoma / secondary. Sarcoma / therapy. Skin Neoplasms / secondary. Skin Neoplasms / therapy. Treatment Outcome. Tumor Burden / drug effects

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17014460.001).
  • [ISSN] 1749-4478
  • [Journal-full-title] Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery
  • [ISO-abbreviation] Clin Otolaryngol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin
  •  go-up   go-down


32. Chang SM, Xing RD, Zhang FM, Duan YQ: Serum soluble CD44v6 levels in patients with oral and maxillofacial malignancy. Oral Dis; 2009 Nov;15(8):570-2
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To determine the levels of serum sCD44v6 in patients with oral cancer and evaluate the value of serum sCD44v6 in adjuvant diagnosis, staging and monitoring treatment response in these patients.
  • One week after treatment, venous blood was collected once again in 60 patients with oral and maxillofacial squamous cell carcinoma (OSCC).
  • The levels of serum sCD44v6 in patients with OSCC and salivary carcinoma showed no difference with those in control group (P > 0.05).
  • Serum sCD44v6 levels in patients with OSCC after treatment became lower than that prevailed during pretreatment (P < 0.05).
  • CONCLUSION: The possible roles of CD44v6 in the diagnosis of oral and maxillofacial malignancy deserve further elucidation and evaluation.
  • Serum sCD44v6 may be a valuable marker in monitoring treatment response in patients with OSCC.
  • [MeSH-major] Antigens, CD44 / blood. Biomarkers, Tumor / blood. Carcinoma, Squamous Cell / blood. Head and Neck Neoplasms / blood. Mouth Neoplasms / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / blood. Carcinoma, Adenoid Cystic / drug therapy. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Mucoepidermoid / blood. Carcinoma, Mucoepidermoid / drug therapy. Carcinoma, Mucoepidermoid / surgery. Case-Control Studies. Female. Humans. Male. Middle Aged. Neoplasm Staging. Reference Values. Salivary Gland Neoplasms / blood. Salivary Gland Neoplasms / drug therapy. Salivary Gland Neoplasms / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19563418.001).
  • [ISSN] 1601-0825
  • [Journal-full-title] Oral diseases
  • [ISO-abbreviation] Oral Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44v6 antigen
  •  go-up   go-down


33. Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Calais G: Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol; 2004 Jan 1;22(1):69-76
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma.
  • PURPOSE: We report the 5-year survival and late toxicity results of a randomized clinical trial, which showed a 3-year improvement in overall survival and locoregional control of stage III or IV oropharynx carcinoma, using concomitant radiochemotherapy (arm B), compared with standard radiotherapy (arm A).
  • PATIENTS AND METHODS: A total of 226 patients were entered onto a phase III multicenter randomized trial comparing radiotherapy alone (70 Gy in 35 fractions; arm A) with concomitant radiochemotherapy (70 Gy in 35 fractions with three cycles of a 4-day regimen comprising carboplatin and fluorouracil; arm B).
  • Five-year late toxicity was evaluated using National Cancer Institute Common Toxicity Criteria for neurological toxicity, hearing, taste, mandibula, and teeth damage, and Radiation Therapy Oncology Group toxicity criteria for skin, salivary gland, and mucosa.
  • Stage IV, hemoglobin level lower than 125 g/L, and standard treatment were independent prognostic factors of short survival and locoregional failure by univariate and multivariate analysis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Combined Modality Therapy. Disease Progression. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intravenous. Injections, Intravenous. Male. Middle Aged. Neoplasm Staging. Prognosis

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2004 Jan 1;22(1):19-22 [14657230.001]
  • (PMID = 14657228.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


34. Agulnik M: Malignancies of the head and neck: the role for molecular targeted agents. Expert Opin Ther Targets; 2007 Feb;11(2):207-17
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment strategies need to evolve and improve upon established therapeutic practices.
  • As the process of cancer evolution is understood to be derived from aberrations in genetic and epigenetic processes, molecularly targeted agents offer attractive therapeutic options by restoring normal control of oncogenic processes.
  • The direct role for the treatment of squamous cell carcinoma of the head and neck, nasopharynx and salivary gland carcinomas with these novel, molecularly targeted agents are reviewed and their potential to improve on the existing standard of care is further explored.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / metabolism. Drug Delivery Systems / methods. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17227235.001).
  • [ISSN] 1744-7631
  • [Journal-full-title] Expert opinion on therapeutic targets
  • [ISO-abbreviation] Expert Opin. Ther. Targets
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Number-of-references] 80
  •  go-up   go-down






Advertisement